Pharmaceutical

ASCO 2024: MediLink’s NSCLC and breast cancer ADC shows early safety success

The clinical-stage biotech will share preliminary safety and efficacy data with its ADC at the 2024 ASCO meeting.

May 25, 2024 - 04:00
ASCO 2024: MediLink’s NSCLC and breast cancer ADC shows early safety success
The clinical-stage biotech will share preliminary safety and efficacy data with its ADC at the 2024 ASCO meeting.
Read the original article

Tags:

Previous Article

First made-in-Singapore antibody-drug conjugate EBC-129 progresses to phase 1B d...

Next Article

ASCO 2024: MSD’s ADC shows efficacy in lung and breast tumours

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

HHS fills key vaccine advisory panel slots

HHS fills key vaccine advisory panel slots

Feb 15, 2024

Zyn scrutiny from Sen. Chuck Schumer prompts an unlikely culture war

Zyn scrutiny from Sen. Chuck Schumer prompts an unlikel...

Jan 26, 2024

Intercept suffers setback with negative AdCom decision for NASH therapy

Intercept suffers setback with negative AdCom decision ...

May 22, 2023